Literature DB >> 12890741

Molecular detection of the G(-248)A BAX promoter nucleotide change in B cell chronic lymphocytic leukaemia.

O Moshynska1, K Sankaran, A Saxena.   

Abstract

BACKGROUND: A novel single nucleotide polymorphism (SNP), G(-248)A, in the 5' untranslated region of the BAX promoter and its association with reduced protein expression, progression beyond Rai stage 0, and treatment resistance in chronic lymphocytic leukaemia (CLL) has been reported previously. AIM: To develop a restriction enzyme analysis (REA) based method for routine detection of BAX promoter SNP in a clinical laboratory.
METHODS: The BAX promoter was analysed in duplicate by REA and sequencing in 90 samples (from 45 patients with CLL, 43 controls, and two cell lines). The promoter region was amplified, digested with restriction endonucleases (Aci I and Tau I), and separated by gel electrophoresis.
RESULTS: After digestion, the normal GG genotype samples produced three distinct bands. The homozygous AA replacement abolished the cleavage site, resulting in a single band. Although the heterozygous samples produced three bands, the two smaller visible bands were reduced in intensity (> 50%). The test characteristics of Aci I REA were better than those of Tau I REA, in terms of sensitivity (100% v 77.8%), specificity (98.6% v 92.3%), positive predictive value (95.03% v 87.4%), and negative predictive value (100% v 85.83%).
CONCLUSIONS: REA using Aci I is a highly sensitive and specific method for detecting the BAX G(-248)A SNP in CLL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890741      PMCID: PMC1187322          DOI: 10.1136/mp.56.4.205

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  27 in total

Review 1.  Chronic lymphocytic leukemia.

Authors:  Neil E Kay; Terry J Hamblin; Diane F Jelinek; Gordon W Dewald; John C Byrd; Sherif Farag; Margaret Lucas; Thomas Lin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2002

Review 2.  B-cell chronic lymphocytic leukemia: a bird of a different feather.

Authors:  F Caligaris-Cappio; T J Hamblin
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

3.  Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.

Authors:  S Kitada; J Andersen; S Akar; J M Zapata; S Takayama; S Krajewski; H G Wang; X Zhang; F Bullrich; C M Croce; K Rai; J Hines; J C Reed
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

4.  Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance.

Authors:  C Pepper; T Hoy; P Bentley
Journal:  Leuk Lymphoma       Date:  1998-01

5.  CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis.

Authors:  S Zupo; L Isnardi; M Megna; R Massara; F Malavasi; M Dono; E Cosulich; M Ferrarini
Journal:  Blood       Date:  1996-08-15       Impact factor: 22.113

6.  Infrequent bax gene mutations in B-cell lymphomas.

Authors:  H Peng; A Aiello; G Packham; P G Isaacson; L Pan
Journal:  J Pathol       Date:  1998-12       Impact factor: 7.996

7.  Biochemical and functional comparisons of Mcl-1 and Bcl-2 proteins: evidence for a novel mechanism of regulating Bcl-2 family protein function.

Authors:  S E Bodrug; C Aimé-Sempé; T Sato; S Krajewski; M Hanada; J C Reed
Journal:  Cell Death Differ       Date:  1995-07       Impact factor: 15.828

8.  Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.

Authors:  N Rampino; H Yamamoto; Y Ionov; Y Li; H Sawai; J C Reed; M Perucho
Journal:  Science       Date:  1997-02-14       Impact factor: 47.728

9.  Association of a novel single nucleotide polymorphism, G(-248)A, in the 5'-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance.

Authors:  Anurag Saxena; Oksana Moshynska; Koravangattu Sankaran; Sathiyanarayanan Viswanathan; David P Sheridan
Journal:  Cancer Lett       Date:  2002-12-10       Impact factor: 8.679

Review 10.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

View more
  10 in total

1.  The role of FAS, FAS-L, BAX, and BCL-2 gene polymorphisms in determining susceptibility to unexplained recurrent pregnancy loss.

Authors:  Rafael Tomoya Michita; Francis Maria Báo Zambra; Lucas Rosa Fraga; Maria Teresa Sanseverino; Lavínia Schuler-Faccini; José Artur Bogo Chies; Priscila Vianna
Journal:  J Assist Reprod Genet       Date:  2019-04-02       Impact factor: 3.412

2.  BAX and CDKN1A polymorphisms correlated with clinical outcomes of gastric cancer patients treated with postoperative chemotherapy.

Authors:  Xiaoting Wang; Youdong Lin; Fenghua Lan; Yinghao Yu; Xuenong Ouyang; Wei Liu; Feilai Xie; Xuzhou Wang; Qiaojia Huang
Journal:  Med Oncol       Date:  2014-09-30       Impact factor: 3.064

3.  The apoptotic response in HCT116BAX-/- cancer cells becomes rapidly saturated with increasing expression of a GFP-BAX fusion protein.

Authors:  Sheila J Semaan; Robert W Nickells
Journal:  BMC Cancer       Date:  2010-10-13       Impact factor: 4.430

4.  Evaluation of Bax and Bak gene mutations and expression in breast cancer.

Authors:  Naglaa Mohamed Kholoussi; Sobhy E H El-Nabi; Nora Nassef Esmaiel; Naser Mohamed Abd El-Bary; Ahmed F El-Kased
Journal:  Biomed Res Int       Date:  2014-02-09       Impact factor: 3.411

5.  BAX and SMAC regulate bistable properties of the apoptotic caspase system.

Authors:  Stephanie McKenna; Lucía García-Gutiérrez; David Matallanas; Dirk Fey
Journal:  Sci Rep       Date:  2021-02-08       Impact factor: 4.379

Review 6.  Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer.

Authors:  Manzar Alam; Shoaib Alam; Anas Shamsi; Mohd Adnan; Abdelbaset Mohamed Elasbali; Waleed Abu Al-Soud; Mousa Alreshidi; Yousef MohammedRabaa Hawsawi; Anitha Tippana; Visweswara Rao Pasupuleti; Md Imtaiyaz Hassan
Journal:  Front Oncol       Date:  2022-03-25       Impact factor: 6.244

7.  Identification of functional DNA variants in the constitutive promoter region of MDM2.

Authors:  Marie-Eve Lalonde; Manon Ouimet; Mathieu Larivière; Ekaterini A Kritikou; Daniel Sinnett
Journal:  Hum Genomics       Date:  2012-09-01       Impact factor: 4.639

8.  Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage.

Authors:  Richard T Libby; Yan Li; Olga V Savinova; Joseph Barter; Richard S Smith; Robert W Nickells; Simon W M John
Journal:  PLoS Genet       Date:  2005-07-25       Impact factor: 5.917

9.  Lack of association between Bax promoter (-248G>A) single nucleotide polymorphism and susceptibility towards cancer: evidence from a meta-analysis.

Authors:  Sushil Kumar Sahu; Tathagata Choudhuri
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

Review 10.  Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer.

Authors:  Christian Sordo-Bahamonde; Seila Lorenzo-Herrero; Ángel R Payer; Segundo Gonzalez; Alejandro López-Soto
Journal:  Int J Mol Sci       Date:  2020-05-25       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.